Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Teriparatide and Calcitonin in Postmenopausal Osteoporosis
NCT00543218Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of teriparatide in osteoporosis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in lumbar spine Bone Mineral Density. Started Dec 2002; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00543218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543218.